GlassScriptPhysician profile
John M Harkless
NPI 1083870455
$5,760.88
in general payments reported to CMS, 2019-2025
38 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $758 · 2021: $989 · 2022: $1,107 · 2023: $763 · 2024: $713 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,006 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,005.86 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,643.41 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $660.31 | 2020-2025 | |
| Novo Nordisk INC | $520.54 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $253.17 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Abbott Laboratories | $249.50 | 2021-2025 | Freestyle Libre 3 |
| Merz North America, INC. | $240.18 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.43 | 2023-2024 | Caplyta |
| Horizon Therapeutics Plc | $234.91 | 2019-2021 | |
| Pfizer INC. | $171.21 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $163.74 | 2020-2025 | Rexulti |
| Amgen INC. | $150.70 | 2019-2021 | |
| Alkermes, INC. | $124.48 | 2022-2025 | Lybalvi |
| Merck Sharp & Dohme LLC | $118.86 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.88 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $70.02 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harkless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.